TY  - GEN
AU  - Jones,J R
AU  - Cairns,D A
AU  - Gregory,W M
AU  - Collett,C
AU  - Pawlyn,C
AU  - Sigsworth,R
AU  - Striha,A
AU  - Henderson,R
AU  - Kaiser,M F
AU  - Jenner,M
AU  - Cook,G
AU  - Russell,N H
AU  - Williams,C
AU  - Pratt,G
AU  - Kishore,B
AU  - Lindsay,J
AU  - Drayson,M T
AU  - Davies,F E
AU  - Boyd,K D
AU  - Owen,R G
AU  - Jackson,G H
AU  - Morgan,G J
TI  - Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial
SN  - 2044-5385
PY  - 2017///1103
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - administration & dosage
KW  - Bortezomib
KW  - Disease-Free Survival
KW  - Female
KW  - Humans
KW  - Hydroxamic Acids
KW  - Kaplan-Meier Estimate
KW  - Lenalidomide
KW  - Male
KW  - Middle Aged
KW  - Multiple Myeloma
KW  - drug therapy
KW  - Neoplasms, Second Primary
KW  - Oligopeptides
KW  - Risk Factors
KW  - Thalidomide
KW  - Vorinostat
N1  - Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
UR  - https://doi.org/10.1038/bcj.2016.114
ER  -